Skip to main content

Meagan E. Deming, MD, PhD

Academic Title:

Assistant Professor

Primary Appointment:




Phone (Primary):



(443) 671-1332

Education and Training

  • Swarthmore College, BA, Biology 2006
  • University of North Carolina-Chapel Hill, Ph.D. in the laboratory of Dr. Ralph Baric, Department of Microbiology and Immunology, 2013
  • University of North Carolina-Chapel Hill, M.D., 2015
  • Residency, University of Maryland School of Medicine, 2017
  • Fellowship, University of Maryland School of Medicine, 2021


Dr. Meagan Deming is a board-certified Infectious Disease specialist with a primary research interest in respiratory viruses, including coronaviruses and influenza. She earned her MD & PhD at the University of North Carolina studying SARS-coronavirus vaccine strategies and antibody neutralization. She has served as a covering physician for COVID-19 vaccine and therapeutic clinical trials, including helping to lead the ‘Mix and Match’ trial studying delayed heterologous SARS-CoV-2 vaccines. Currently an assistant professor at the University of Maryland Center for Vaccine Development and Global Health, she is an active investigator in the CIVICs network, working on an influenza challenge study as well as influenza vaccine clinical trials, and is PI for the 'SNIFF study' exploring asymptomatic SARS-CoV-2 infections after vaccination.

Research/Clinical Keywords

Coronavirus, Influenza, vaccine, therapeutics, SARS, SARS-CoV-2, CoVID19, clinical vaccine trials, human challenge studies, controlled human infection

Highlighted Publications


  1. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, Sahly HM El, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck Jr RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O’Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH, DMID 21-0012 Study Group. Homologous and Heterologous Covid-19 Booster Vaccinations. NEJM. 2022 DOI: 10.1056/NEJMoa2116414. PMID 35081293
  2. Deming ME, Lyke KE. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nature Med (2021) DOI:10.1038/s41591-021-01463-x
  3. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models. N Engl J Med. 2020; 63(1):1969–73. DOI:10.1056/NEJMp2020076. PMID: 32610006; PMCID: PMC7968616
  4. Niang M*, Deming ME*, Goudiaby D, Diop OM, Dia N, Diallo A, Ortiz JR, Diop D, Lewis KDC, Lafond KE, Widdowson M, Victor JC, Neuzil KM. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: results from a cluster-randomized trial. Vaccine 2020 Nov 3;38(47):7526-7532. DOI:10.1016/j.vaccine.2020.09.059. PMID: 33012603; PMCID: PMC7936169
  5. Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: Viral determinants of interspecies transmission. Curr Opin Virol; 2011; 1(6):624–634. DOI:10.1016/j.coviro.2011.10.012. PMID: 22180768; PMCID: PMC3237677.
  6. Bolles M*, Deming D*, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.J Virol. 2011 Dec;85(23):12201-15. DOI:10.1128/JVI.06048-11. PMID: 21937658; PMC3209347.


Additional Publication Citations


  • Rani M, Bolles M, Donaldson EF, Van Blarcom T, Baric R, Iverson B, Georgiou G. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.J Virol. 2012 Sep;86(17):9113-21. doi: 10.1128/JVI.00233-12. Epub 2012 Jun 13. PMID: 22696652; PMCID: PMC3416138.
  • Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease.Nat Med. 2012 Dec;18(12):1820-6. doi: 10.1038/nm.2972. Epub 2012 Nov 11. PMID: 23142821; PMC3518599.
  • Gralinski LE, Bankhead A 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. 2013 Aug 6;4(4). pii: e00271-13. doi: 10.1128/mBio.00271-13. PMID: 23919993; PMC3747576.
  • Aevermann BD, Pickett BE, Kumar S, Klem EB, Agnihothram S, Askovich PS, Bankhead A 3rd, Bolles M, Carter V, Chang J, Clauss TRW, Dash P, Diercks AH, Eisfeld AJ, Ellis A, Fan S, Ferris MT, Gralinski LE, Green RR, Gritsenko MA, Hatta M, Heegel RA, Jacobs JM, Jeng S, Josse L, Kaiser SM, Kelly S, Law GL, Li C, Li J, Long C, Luna ML, Matzke M, McDermott J, Menachery V, Metz TO, Mitchell H, Monroe ME, Navarro G, Neumann G, Podyminogin RL, Purvine SO, Rosenberger CM, Sanders CJ, Schepmoes AA, Shukla AK, Sims A, Sova P, Tam VC, Tchitchek N, Thomas PG, SC Tilton, Totura T, Wang J, Webb-Robertson B, Wen J, Weiss JM, Yang F, Yount B, Zhang Q, McWeeney S, Smith RD, Waters KM, Kawaoka Y, Baric R, Aderem A, Katze MG Scheuermann RH. A comprehensive collection of systems biology data characterizing the host response to viral infection.Sci Data. 2014 Oct 14;1:140033. doi: 10.1038/sdata.2014.33. eCollection 2014. PMID: 25977790; PMC4410982.
  • Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.J Virol. 2014 Dec;88(23):13769-80. PMID: 25231316; PMCID: PMC4248992.
  • Graham RL, Deming DJ, Deming ME, Yount BL, Baric RS. Evaluation of a recombination-resistant coronavirus as a broadly applicable rapidly implementable vaccine platform. Communications Biology. 2018 Oct 29;1(179):1-10. PMID: 30393776; PMCID: PMC6206136.
  • Deming M, Mark A, Nyemba V, Heil EL, Palmeiro RM, Schmalzle SA. Cognitive biases and knowledge deficits leading to delayed recognition of cryptococcal meningitis. IDCases 2019;18:e00588. PMID 31360635; PMCID: PMC6639654
  • Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020;17(9):1–16. PMID 32355503; PMCID: PMC7187507
  • Deming ME, Chen WH. COVID-19 and Lessons to be Learned from Prior Coronavirus Outbreaks. Ann Am Thorac Soc. 2020;17(7): 790-794. PMID: 32267164; PMCID: PMC7328171
  • Niang M*, Deming ME*, Goudiaby D, Diop OM, Dia N, Diallo A, Ortiz JR, Diop D, Lewis KDC, Lafond KE, Widdowson M, Victor JC, Neuzil KM. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: results from a cluster-randomized trial. Vaccine 2020 Nov 3;38(47):7526-7532. DOI:10.1016/j.vaccine.2020.09.059. PMID: 33012603
  • Barnabas R V., Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang M-L, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Ann Intern Med. 2021; 174(3):344-352. doi:10.7326/M20-6519. PMID: 33284679; PMCID: PMC7732017
  • So JY, O’Hara NN, Kenaa B, Williams JG, deBorja CL, Slejko JF, Zafari Z, Sokolow M, Paul Zimand P, Deming M, Marx J, Pollak AN, Reed Decline in COPD Admissions During the COVID-19 Pandemic Associated with Lower Burden of Community Respiratory Viral Infections. Am J Med. 2021; DOI:10.1016/j.amjmed.2021.05.008.
  • Strohmeier S, Amanat F, Zhu X, McMahon M, Deming M, Pasetti M, Neuzil K, Wilson I, Krammer F. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio. 2021; DOI: 10.1128/mBio.02241-21. PMID 34809451; PMC860935
  • Friedman-Klabanoff DJ, Fitzpatrick MC, Deming ME, Agrawal V, Sitar S, Schaafsma T, Brown E, Neuzil KM, Barnabas R V, Laufer MK, Team HC-19 PEPS. Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission. J Infect Dis. 2022 Feb 2;jiac029.
  • Deming ME, Dong TQ, Agrawal V, Mills MG, Huang M-LW, Greninger AL, Jerome KR, Wener MH, Paasche-Orlow MK, Kissinger P, Luk A, Hoffman RM, Stewart J, Kottkamp AC, Bershteyn A, Chu HY, Stankiewicz Karita HC, Johnston CM, Wald A, Barnabas R, Brown E, Neuzil K. Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. J Infect Dis. 2022 Feb 12;jiac048. DOI: 10.1093/infdis/jiac048. PMID 35150571


Clinical Specialty Details

Dr. Deming is a board-certified Infectious Disease specialist. She attends on the transplant infectious disease consult service, on which she also teaches medical students, residents, and fellows. 

Awards and Affiliations

2022 Passano Clinician-Scholar

2018-2020 T32 Vaccinology Research fellowship

2018 Fellow Teacher of the Year Award, Division of Infectious Diseases, University of Maryland School of Medicine

Grants and Contracts

Meagan Deming, MD, PhD (PI)


IDCRC New Investigator Pilot Award

Seasonal Coronavirus Immunity and Effects on SARS-CoV-2 Immune Response